Patents by Inventor Harald Renz

Harald Renz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180171339
    Abstract: The present invention relates to the preparation of a medicinal agent comprising DNAzymes according to Seq. ID 2-62 for the prophylaxis and treatment of virus infections that are caused by picornaviruses, in particular by rhinoviruses, in particular for the prophylaxis and treatment of rhinitis, head colds, asthma, COPD and viral infections of the upper respiratory tract.
    Type: Application
    Filed: May 13, 2016
    Publication date: June 21, 2018
    Applicant: Secarna Pharmaceuticals GmbH & Co KG
    Inventors: Daniel POTACZEK, Holger GARN, Harald RENZ
  • Patent number: 9950017
    Abstract: The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and/or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: April 24, 2018
    Assignees: FORSCHUNGSZENTRUM BORSTEL, RUHR-UNIVERSIT√ĄT BOCHUM
    Inventors: Albrecht Bufe, Otto Holst, Harald Renz, Erika Von Mutius, Johann Bauer, Nicole Blumer, Jennifer Debarry, Markus Ege, Susanne Friedrich, Holger Garn, Soren Gatermann, Anna Hanuszkiewicz, Holger Heine, Michael Wegmann
  • Patent number: 8247544
    Abstract: A DNAzyme is disclosed, which comprises: (i) a catalytic domain with a nucleotide sequence GGCTAGCTACAACGA or a modified sequence of comparable biological effect, which cleaves T-bet mRNA at every purine-pyrimidine binding site to which it is bound; (ii) a right substrate binding domain which is contiguous with the 3?-end of the catalytic domain; and (iii) a left substrate binding domain which is contiguous with the 5?-end of the catalytic domain, whereby the two substrate binding domains are respectively complementary to two regions of the T-bet mRNA so that they hybridize with the mRNA; are active in vivo; and contain the sequences td 69 GGCAATGAA GGC TAGCTACAACGA TGGGTTTCT or td70 TCACGGCAA GGCTAGCTACAACGA GAACTGGGT.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: August 21, 2012
    Assignee: Sterna Biologicals GmbH & Co. KG
    Inventors: Serdar Sel, Harald Renz
  • Patent number: 8119789
    Abstract: The present invention relates to a method for producing of a cell and/or tissue and/or disease phase specific medicament against against chronic inflammatory diseases. Disease, cell type, tissue and/or stage specific proteins and nucleic acids are identified with regard to their modified expression pattern and the corresponding nucleic acids are analyzed as possible attack targets for DNAzymes or siRNA. What follows is a design of active specific DNAzymes and siRNA which bind to the target sequence and cleave it such that a medicament against chronic inflammatory diseases and autoimmune diseases is provided.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: February 21, 2012
    Assignee: Sterna Biologicals GmbH & Co. KG
    Inventors: Serdar Sel, Harald Renz
  • Publication number: 20110217402
    Abstract: A process for the preparation of a non-viable probiotic composition having anti-allergic (i.e. allergy preventive and/or anti-allergic in a therapeutic sense) properties, the process including the steps of (a) subjecting LGG to cultivation in a suitable culture medium using a batch process; (b) harvesting the culture supernatant at a late exponential phase of the cultivation step; (c) removing liquid contents from the culture supernatant so as to obtain the composition. Also, a composition comprising a proteinaceous mixture, said composition being obtainable by the above process, and the use thereof in a dietetic product preferably for targeting expecting mother's, infants, or children as well as application in food for specific medical purposes.
    Type: Application
    Filed: September 10, 2010
    Publication date: September 8, 2011
    Applicant: Mead Johnson Nutrition Company
    Inventors: Eric A.F. van Tol, William Michael Russell, Udo Herz, Harald Renz, Holger Garn, Machtelt Braaksma, Maria Johanna van der Werf, Karin M. Overkamp
  • Publication number: 20110190377
    Abstract: A DNAzyme is disclosed, which comprises: (i) a catalytic domain with a nucleotide sequence GGCTAGCTACAACGA or a modified sequence of comparable biological effect, which cleaves T-bet mRNA at every purine-pyrimidine binding site to which it is bound; (ii) a right substrate binding domain which is contiguous with the 3?-end of the catalytic domain; and (iii) a left substrate binding domain which is contiguous with the 5?-end of the catalytic domain, whereby the two substrate binding domains are respectively complementary to two regions of the T-bet mRNA so that they hybridize with the mRNA; are active in vivo; and contain the sequences td 69 GGCAATGAA GGC TAGCTACAACGA TGGGTTTCT or td70 TCACGGCAA GGCTAGCTACAACGA GAACTGGGT.
    Type: Application
    Filed: March 1, 2011
    Publication date: August 4, 2011
    Inventors: Serdar SEL, Harald Renz
  • Patent number: 7923006
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: April 12, 2011
    Assignee: Mead Johnson Nutrition Company
    Inventors: Udo Herz, Nicole Bluemer, Harald Renz, Holger Garn
  • Patent number: 7867486
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: January 11, 2011
    Assignee: Mead Johnson Nutrition Company
    Inventors: Udo Herz, Nicole Bluemer, Harald Renz, Holger Garn
  • Patent number: 7867485
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: January 11, 2011
    Assignee: Mead Johnson Nutrition Company
    Inventors: Udo Herz, Nicole Bluemer, Harald Renz, Holger Garn
  • Patent number: 7837989
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: November 23, 2010
    Assignee: Mead Johnson Nutrition Company
    Inventors: Udo Herz, Nicole Bluemer, Harald Renz, Holger Garn
  • Publication number: 20100249216
    Abstract: The invention relates to a method for the production of a cell and/or tissue and/or disease phase specific medicament against chronic inflammatory diseases. Disease, cell-type, tissue and/or stage specific proteins and nucleic acids are identified with regard to the modified expression pattern and the corresponding nucleic acids are analyzed as possible attack targets for DNAzymes or siRNA. What follows is a design of active specific DNAzymes and siRNA which bind to the target sequence and cleave it such that a medicament against chronic inflammatory diseases and auto-immune diseases is provided.
    Type: Application
    Filed: October 1, 2004
    Publication date: September 30, 2010
    Inventors: Serdar Sel, Harald Renz
  • Publication number: 20080305089
    Abstract: The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and/or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.
    Type: Application
    Filed: March 3, 2008
    Publication date: December 11, 2008
    Applicant: Protectimmun GmbH
    Inventors: Albrecht Bufe, Otto Holst, Harald Renz, Erika von Mutius, Johann Bauer, Nicole Blumer, Jennifer Debarry, Markus Ege, Susanne Friedrich, Holger Garn, Soren Gatermann, Anna Hanuszkiewicz, Holger Heine, Michael Wegmann
  • Publication number: 20080131413
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Application
    Filed: October 19, 2007
    Publication date: June 5, 2008
    Inventors: Udo Herz, Harald Renz, Nicole Bluemer, Holger Garn
  • Publication number: 20080118485
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 22, 2008
    Inventors: Udo Herz, Harald Renz, Nicole Bluemer, Holger Gran
  • Publication number: 20080118483
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 22, 2008
    Inventors: Udo Herz, Harald Renz, Nicole Bluemer, Holger Garn
  • Publication number: 20080118484
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 22, 2008
    Inventors: Udo Herz, Harald Renz, Nicole Bluemer, Holger Garn
  • Publication number: 20080085267
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Application
    Filed: October 19, 2007
    Publication date: April 10, 2008
    Inventors: Udo Herz, Harald Renz, Nicole Bluemer, Holger Garn
  • Patent number: 7303745
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: December 4, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Udo Herz, Harald Renz, Nicole Bluemer, Holger Garn
  • Publication number: 20060233773
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Application
    Filed: June 3, 2005
    Publication date: October 19, 2006
    Inventors: Udo Herz, Harald Renz, Nicole Bluemer, Holger Garn
  • Publication number: 20060233772
    Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.
    Type: Application
    Filed: April 15, 2005
    Publication date: October 19, 2006
    Inventors: Udo Herz, Harald Renz